Protein/Antibody Development

Protein/Antibody drug discovery and development is the process of identifying new therapeutic antibodies to combat different diseases. These antibody therapeutics can become in a number of different formats, such as full length antibodies, bispecific antibodies, antibody fragments, and more. Conventional approaches for the discovery and pre-clinical development take two to three years, Protheragen’s technologies, based on artificial intelligence (AI), machine learning (ML), allow shrinking this time to a few weeks.

Hybridoma Development Antigen Production Antibody Sequencing Hybridoma Stabilization Chemical Antibody Generation Antibody Humanization Antibody Affinity Maturation In Vivo Efficacy and Safety Epitope Mapping Antibody/Protein Characterization Antibody Transient Expression Antibody Stable Cell Line Antibody Production Protein/Antibody Drug Development In Vitro Assay and Screening

Figure 1 Protein/Antibody Drug Development Overview

nomain-drag-pic1Therapeutic Antibodies Discovery Process

  • nomain-title-log-pic2 Target Identification and Validation
    Molecular targets are generally receptors or antigens expressed on the outside of a cell. Biochemical methods, genetic interactions, and computational inference are common methods used to identify specific target, revealing the antibody-antigen binding mechanism.
  • nomain-title-log-pic2 Antibody Lead Generation
    In the phase of antibody lead generation, validated molecular targets are used as antigens to initiate an immune response in a host animal to generate therapeutic antibody candidates.
  • nomain-title-log-pic2 Antibody Lead Optimization
    Antibody-based drug candidate is modified to increase their effectiveness, affinity, and to diminish immunogenicity. In this stage, rodent monoclonal antibodies are converted to their humanized forms.
  • nomain-title-log-pic2 Antibody Lead and Functionality Analysis
    This is an important part of the discovery stage of therapeutic antibody discovery and development. Antibody lead and functionality analysis include in vitro and in vivo testing to further evaluate potential drug candidates. It’s necessary to check their feasibility and efficiency.
  • nomain-title-log-pic2 Antibody Production and Preclinical Development
    This is the final stage of preclinical development, where antibody-based drug candidate selection and recombinant expression are conducted.
  • nomain-title-log-pic2 Preclinical Research
    The safety of the lead is checked before clinical trials in this phase. Then the new therapeutic antibody drug is manufactured for clinical testing.
  • nomain-title-log-pic2 Clinical Phase
    Assess the safety and efficacy of the drug and how it compares to the current treatment options, until finally tested through clinical trials and approved for distribution to patients.

nomain-drag-pic1Technical Services Driven by Artificial Intelligence

Artificial intelligence is capable of reducing high costs in drug research and development as it finds solutions faster and with precision. Protheragen implements AI-driven solutions for the development of therapeutic antibodies, as bio-drugs are used in an increasing number of pathologies, including oncology. Protheragen’s objective is to propose a software suite that creates a formal approach of antibody development, reducing the risks of failure and the duration of pre-clinical steps, as well as strengthening intellectual protection.

Online Inquiry

Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.

Please input "protheragen" as verification code.

  • 2200 Smithtown Avenue, Room 1, Ronkonkoma, NY 11779-7329, USA
  • Phone: 1-516-666-0889
  • Fax: 1-516-927-0118
  • Email:


Copyright © 2005-2020 [ Protheragen ] All Rights Reserved.